Self-reported Transportation Barriers to Health Care among US Cancer Survivors

Changchuan Jiang; K. Robin Yabroff; Lei Deng; Qian Wang; Stuthi Perimbeti; Charles L. Shapiro; Xuesong Han

doi:10.1001/jamaoncol.2022.0143

Self-reported Transportation Barriers to Health Care among US Cancer Survivors

Changchuan Jiang, K. Robin Yabroff, Lei Deng, Qian Wang, Stuthi Perimbeti, Charles L. Shapiro, Xuesong Han

Research output: Contribution to journal › Letter › peer-review

27 Scopus citations

Original language	English
Pages (from-to)	775-778
Number of pages	4
Journal	JAMA Oncology
Volume	8
Issue number	5
DOIs	https://doi.org/10.1001/jamaoncol.2022.0143
State	Published - May 2022

Access to Document

10.1001/jamaoncol.2022.0143

Cite this

@article{fb71b2c65faf40849d6cc53407f6aa75,

title = "Self-reported Transportation Barriers to Health Care among US Cancer Survivors",

author = "Changchuan Jiang and Yabroff, {K. Robin} and Lei Deng and Qian Wang and Stuthi Perimbeti and Shapiro, {Charles L.} and Xuesong Han",

note = "Funding Information: support from Miltenyi Biotec. Dr Aschenbrenner reported receiving personal fees for serving on speakers{\textquoteright} bureaus for Astellas, Kite, Sanofi Genzyme, and Incyte and on advisory boards for Astellas, Incyte, Omeros, EUSA Pharma, and Janssen, all outside the submitted work. Dr Fenske reported receiving research funding from Novartis, Portola, Curis, and TG Therapeutics; and receiving consulting and/or speaking fees from Adaptive Biotechnologies, ADC Therapeutics, AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Biogen, CSL Therapeutics, Karyopharm, Kite (Gilead), Kyowa, MorphoSys, Pharmacyclics, Sanofi, Servier Pharmaceuticals, TG Therapeutics, and Verastem, all outside the submitted work. Dr Hamadani reported receiving research support and/or funding from Takeda, ADC Therapeutics, Spectrum Pharmaceuticals, and Astellas; receiving institution research funding from Janssen R&D, Celgene, Merck, MedImmune, Seattle Genetics (now Seagen), and Millennium Pharmaceuticals; receiving consulting fees from Incyte, ADC Therapeutics, Omeros, MorphoSys, Kite, Genmab, Seagen, Gamida Cell, and Novartis; and receiving speakers{\textquoteright} bureau fees from Sanofi Genzyme, AstraZeneca, BeiGene, and ADC Therapeutics, all outside the submitted work. Dr Hari reports receiving grants and personal fees from Bristol Myers Squibb/Celgene, Takeda, Amgen, and Janssen; receiving personal fees from Legend, Sanofi Genzyme, Karyopharm, AbbVie, and GlaxoSmithKline; and being employed by Iovance, all outside the submitted work. Dr Shah reports participating on advisory boards and receiving personal/consulting fees for Kite Pharma, TG Therapeutics, Miltenyi Biotec, Lilly, Bristol Myers Squibb, Epizyme, Legend, Incyte, Novartis, and Umoja; and receiving research funding and honoraria from Lilly, Miltenyi Biotec, Epizyme, Novartis, and Umoja, all outside the submitted work. No other disclosures were reported.",

year = "2022",

month = may,

doi = "10.1001/jamaoncol.2022.0143",

language = "English",

volume = "8",

pages = "775--778",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "5",

}

TY - JOUR

T1 - Self-reported Transportation Barriers to Health Care among US Cancer Survivors

AU - Jiang, Changchuan

AU - Yabroff, K. Robin

AU - Deng, Lei

AU - Wang, Qian

AU - Perimbeti, Stuthi

AU - Shapiro, Charles L.

AU - Han, Xuesong

N1 - Funding Information: support from Miltenyi Biotec. Dr Aschenbrenner reported receiving personal fees for serving on speakers’ bureaus for Astellas, Kite, Sanofi Genzyme, and Incyte and on advisory boards for Astellas, Incyte, Omeros, EUSA Pharma, and Janssen, all outside the submitted work. Dr Fenske reported receiving research funding from Novartis, Portola, Curis, and TG Therapeutics; and receiving consulting and/or speaking fees from Adaptive Biotechnologies, ADC Therapeutics, AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Biogen, CSL Therapeutics, Karyopharm, Kite (Gilead), Kyowa, MorphoSys, Pharmacyclics, Sanofi, Servier Pharmaceuticals, TG Therapeutics, and Verastem, all outside the submitted work. Dr Hamadani reported receiving research support and/or funding from Takeda, ADC Therapeutics, Spectrum Pharmaceuticals, and Astellas; receiving institution research funding from Janssen R&D, Celgene, Merck, MedImmune, Seattle Genetics (now Seagen), and Millennium Pharmaceuticals; receiving consulting fees from Incyte, ADC Therapeutics, Omeros, MorphoSys, Kite, Genmab, Seagen, Gamida Cell, and Novartis; and receiving speakers’ bureau fees from Sanofi Genzyme, AstraZeneca, BeiGene, and ADC Therapeutics, all outside the submitted work. Dr Hari reports receiving grants and personal fees from Bristol Myers Squibb/Celgene, Takeda, Amgen, and Janssen; receiving personal fees from Legend, Sanofi Genzyme, Karyopharm, AbbVie, and GlaxoSmithKline; and being employed by Iovance, all outside the submitted work. Dr Shah reports participating on advisory boards and receiving personal/consulting fees for Kite Pharma, TG Therapeutics, Miltenyi Biotec, Lilly, Bristol Myers Squibb, Epizyme, Legend, Incyte, Novartis, and Umoja; and receiving research funding and honoraria from Lilly, Miltenyi Biotec, Epizyme, Novartis, and Umoja, all outside the submitted work. No other disclosures were reported.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85127624134&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2022.0143

DO - 10.1001/jamaoncol.2022.0143

M3 - Letter

C2 - 35323841

AN - SCOPUS:85127624134

SN - 2374-2437

VL - 8

SP - 775

EP - 778

JO - JAMA Oncology

JF - JAMA Oncology

IS - 5

ER -